111 results about "Cholangeitis" patented technology

The invention relates to application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of a medicine for resisting cholestatic liver diseases, and belongs to the technical field of medicinal chemistry. The 1, 2, 3, 4, 6-O-pentagalloylglucose provided by the invention can be used for promoting bile acid excretion by reducing WDR6 protein expression. In-vivo and in-vitro experiments prove that the 1, 2, 3, 4, 6-O-pentagalloylglucose can be used for remarkably relieving the symptom of the cholestatic liver disease. In addition, the 1, 2, 3, 4, 6-O-pentagalloylglucose has no obvious toxic or side effect, and has no obvious influence on the liver function and the kidney function. The 1, 2, 3, 4, 6-O-pentagalloylglucose has a wide anti-cholestatic liver disease spectrum, and is suitable for various cholestatic liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and the like.

The invention discloses an application of probiotics in preparation of a medicine for preventing and / or treating cholestatic liver diseases. The probiotics are selected from one or more of plant lactobacillus Lp-G18, bifidobacterium longum subsp. Longum BL-G301, lactobacillus reuteri LR-G100 and lactobacillus johnsonii LJ-G55. Preferably, the cholestatic liver disease is primary biliary cholangitis.

The invention relates to the field of biomedicine, particularly provides a copper-based nano-enzyme as well as a preparation method and application thereof, and aims to solve the problems that in the prior art, clinical treatment on primary sclerosing cholangitis (PSC) is difficult in diagnosis and lacks of effective treatment drugs. The copper-based nano-enzyme comprises a nano-enzyme carrier and a copper-based nano-enzyme, wherein the nano-enzyme carrier is a two-dimensional nanosheet formed by copper ions, gallic acid and ursodesoxycholic acid through coordinate bonds; the probe molecule is a cyanine dye molecule connected to the surface of the nano-enzyme carrier through a covalent bond; wherein the fluorescence intensity of the copper-based nano enzyme is enhanced after the action of the alkaline phosphatase. The three functions of alkaline phosphatase responsive diagnosis, nano-enzyme catalytic treatment and ursodesoxycholic acid hepatic targeting are innovatively and synergistically integrated into one nano platform, the treatment function can be executed while specific imaging diagnosis is performed on diseases, and a new strategy is provided for diagnosis and treatment of diseases such as PSC.

The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

The disclosure relates to methods of (i) treating a subject for a liver fibrotic disease, in particular, primary sclerosing cholangitis or (ii) modulating αVβ6 integrin, αVβ1 integrin, or both αVβ6 integrin and αVβ1 integrin in a subject in need thereof, comprising administration of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4- ylamino)butanoic acid, or a pharmaceutically acceptable salt thereof as described herein. Optionally, a second drug, such as ursodeoxycholic acid or a pharmaceutically acceptable salt thereof, can be co-administered. The compounds and pharmaceutical compositions thereof are αVβ6 integrin inhibitors that are useful for treating fibrosis such as primary sclerosing cholangitis.

To provide methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC).SOLUTION: The present invention provides a method comprising administering to the patient an agonist of the Macrophage Stimulating 1 (MST1) / Macrophage Stimulating 1 Receptor (MST1R) pathway.SELECTED DRAWING: None

The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1, 5-a]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

This invention relates to the use of a recombinant protein ANG in the preparation of medicaments for treating cholestatic liver disease. Specifically, this invention provides the use of the angiopoietin ANG gene, or its protein, or its promoter, for the preparation of medicaments, compositions, or formulations for the prevention, improvement, and / or treatment of cholestatic liver disease. It is particularly effective in treating primary biliary cholangitis and primary sclerosing cholangitis.

The present invention relates to the technical field of liver-protecting formula compositions, and in particular, to a liver-protecting milk thistle formula composition, and a preparation method thereof. Technical problems: the liver-protecting milk thistle formula composition, and a preparation method thereof are intended to solve the technical problems that most of existing liver-protecting compositions in the prior art are designed for the general liver protection needs of the general population and cannot specifically treat liver damage caused by excessive alcohol intake and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia. Technical solution: a liver-protecting milk thistle formula composition, including the following components: silymarin, puerarin, artichoke extract, glutathione, dandelion extract, and GABA. The liver-protecting formula composition has a good therapeutic effect on liver damage caused by excessive alcohol intake, and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia.

The invention provides a biomarker for diagnosing primary biliary cholangitis and application of the biomarker, and belongs to the technical field of biomarkers. The biomarker disclosed by the invention comprises serum protein and / or N-glycopeptide. According to the method, the improvement of PBC diagnosis is taken as a starting point, the serum protein and the N-glycopeptide are taken as screening templates, a more accurate non-invasive prediction means for differential diagnosis of PBC is provided, and a theoretical basis is provided for rapid and accurate diagnosis of PBC.

The application relates to the field of biological medicine, and discloses application of folic acid in prevention, diagnosis and treatment of genetic, infectious or allergic diseases. The application finds that the folic acid can achieve the prevention and treatment effects on the genetic, infectious or allergic diseases by improving inflammation, regulating iron ion metabolism, correcting intestinal flora disorder, reducing liver / intestinal tissue damage, inhibiting expression of inflammatory factors and promoting expression of Nox2. Meanwhile, the application provides application of one or more of the folic acid, S100a8, S100a9, Nox2 and IFN-gamma as a diagnostic or auxiliary diagnostic marker of biliary atresia. Meanwhile, the application provides the folic acid or a derivative thereof, which is prepared into food, a nutritional preparation or a medicine and applied to children or adults, so as to achieve the purposes of preventing and treating biliary atresia, cholangitis, jaundice, infectious diseases, intestinal diseases and diseases caused by abnormal folic acid metabolism.

The present invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of elafibranor, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-propyl]phenoxy]-2-methylpropanoic acid (GFT1007), and a pharmaceutically acceptable salt of elafibranor or GFT1007, for use in a method for reducing fatigue in subject having primary biliary cholangitis (PBC). The pharmaceutical composition of the invention provides a significative reduction of the PROMIS Fatigue T-score (PROMIS Short Form - Fatigue 7a questionnaire (V1.0)) from baseline in a subject having PBC.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation and / or fibrosis in the liver, e.g., metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), primary biliary cholangitis, primary sclerosing cholangitis, alcoholic cirrhosis, hepatitis cirrhosis, cholestasis, autoimmune hepatitis, viral hepatitis B, viral hepatitis C, hemochromatosis, Wilson's disease, or alcoholic steatohepatitis, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

The present invention relates to a pharmaceutical composition comprising elafibranor or a pharmaceutically acceptable salt thereof for use in treating primary biliary cholangitis (PBC) in subjects intolerant to ursodeoxycholic acid (UDCA).

The invention relates to the treatment of ascites, and especially refractory ascites, with an orally bioavailable prodrug of dopamine. A preferred prodrug of dopamine is docarpamine. In one embodiment treated patients are, prior to treatment, on doses of furosemide >80 mg / day and / or spironolactone >100 mg / day or equivalent doses of an alternative loop-acting and / or distal-acting diuretic. The ascites treated by the invention are typically caused by liver cirrhosis due to alcohol or non-alcoholic fatty liver disease and generally not due to viral hepatitis or primary biliary cholangitis. Typical patients have an activated renin-angiotensin-aldosterone levels as may be indicated by elevated levels of renin and / or aldosterone. Refractory ascites treatable according to the invention are such that patients beginning treatment require large volume paracentesis at a minimum of: (a) 3 times in 60 days, (b) 4 times in 90 days or (c) at least once every 30 days over a 90-day period. The invention also contemplates treating diuretic intractable ascites. Target plasma dopamine levels are disclosed by with dosing with the contemplated dopamine prodrugs may be guided. Preferred dosing is greater that 2250 mg per day, with more preferred doses exceeding 3500 mg per day.

The invention discloses application of a miR-497a-5p inhibitor in preparation of a medicine for preventing or treating liver diseases, and the miR-497a-5p gene can be used as a regulation target or a regulation marker in the medicine for preventing or treating the liver diseases. The liver diseases include non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), alcoholic fatty liver disease (AFLD), hepatic fibrosis, or cirrhosis. The invention proves that the miR-497a-5p inhibitor can be used for preventing or treating the liver diseases on an animal model of the liver related diseases.

The present application provides a kind of PRMT5 inhibitor, PRMT5 inhibitor includes: recombinant adeno-associated virus vector AAV-shPrmt5 and GSK3326595;Recombinant adeno-associated virus vector AAV-shPrmt5 includes the shRNA of targeting PRMT5, the nucleotide sequence of shRNA is as shown in SEQ ID No:1.The present application also provides the application of the above-mentioned PRMT5 inhibitor in the preparation of drug for improving primary biliary cholangitis, PRMT5 inhibitor is all PRMT5 gene / protein as target point, by inhibiting the expression of PRMT5 gene / protein, reduce liver tissue and spleen tissue Tfh cell and GC B cell, serum autoantibody and transaminase level, can effectively delay the disease progression of primary biliary cholangitis.

The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives of Formula (I): or a salt or prodrug thereof. These compounds are TLR9 inhibitors useful for the treatment, prevention or slowing of a fibrotic disease, such as liver fibrosis, kidney fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic nephropathy, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

Described herein are methods of modulating ABCB11 gene transcription using antisense oligonucleotides (ASOs) targeting regulatory RNAs, such as promoter-associated RNAs and enhancer RNAs. These methods are useful for increasing the expression of ABCB11 mRNA and protein to treat subjects having or at risk of developing cholestasis or a cholestatic liver disease, such as primary biliary cholangitis and progressive familial intrahepatic cholestasis.

The invention provides a construction method and system of an acute obstructive suppurative cholangitis conservative treatment failure risk prediction model. The construction method comprises the following steps: S1, collecting clinical and laboratory index data of a plurality of cases of acute obstructive suppurative cholangitis patients conforming to a containing and discharging standard, preprocessing the clinical and laboratory index data, and then dividing the clinical and laboratory index data into a training set and a test set; s2, for the data of the training set, balancing is carried out by adopting an ROSE algorithm, and then feature screening is carried out by sequentially utilizing Spearman correlation analysis, single-factor ROC analysis and LASSO regression; s3, taking whether the patient is aggravated or not within 24 hours as a dependent variable, taking the features as independent variables, establishing a prediction model by adopting multivariable logistic regression, and optimizing model parameters through 10-fold cross validation; and S4, performing model performance verification evaluation based on the test set. The early prediction precision is significantly improved, and risk layering and treatment decision quantification are realized.

The present invention relates to 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

The present invention aims to provide a specific test method for ulcerative colitis and primary sclerosing cholangitis. The present invention first provides a test method for ulcerative colitis, providing a test process for detecting antibodies that immunoreact with integrin αVβ6 and / or antibodies that immunoreact with integrin αVβ3 in a sample as an indicator of ulcerative colitis. The present invention secondly provides a test method for primary sclerosing cholangitis, providing a test process for detecting antibodies that immunoreact with integrin αVβ6 in a sample as an indicator of primary sclerosing cholangitis.

The present invention provides a bile duct drainage tube for preventing duodenal papilla bleeding, comprising a drainage tube body, an inner core and a pusher; the head tube section of the drainage tube body is provided with at least two side holes, the middle tube section of the drainage tube body is attached with a cylindrical balloon, the tail tube section of the drainage tube body is provided with a one-way injection valve, the head of the injection valve is connected with the balloon; the balloon is cylindrical after being filled; the head of the inner core includes a channel I and a needle tube, the channel I is inserted into the lumen of the drainage tube body and passes out, and the needle tube is inserted through the tail end of the injection valve; the tail of the inner core is located in the lumen of the pusher; the tail includes a channel II connected with the channel I and a channel III connected with the needle tube; the base of the inner core is provided with a channel IV connected with the channel II and a channel V connected with the channel III, and the channel V is connected with a balloon injection connector. While draining bile, the filled balloon can compress the duodenal papilla sphincter, and can prevent the occurrence of postoperative cholangitis and duodenal papilla bleeding.

The invention provides compounds of formula (I), stereoisomers, tautomers, or pharmaceutically acceptable salts thereof for use in preventing, inhibiting or treating a condition or disorder which is mediated by urocanate reductase: (I) wherein A is a 5-membered heteroaromatic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur, and in which at least one of said heteroatoms is nitrogen; R1 and R2 are independently selected from: -H; C1-6 alkyl; C1-6 haloalkyl; C1-6 alkoxy; halogen; and -CN; when present, each R3 is independently selected from: C1-6 alkyl; C1-6 haloalkyl; C1-6 alkoxy; halogen; -OH; -CN; -NO2; -NR5R6 wherein R5 and R6 are independently selected from H and C1-3 alkyl; and -C(=NR7)(NR8R9) wherein each of R7, R8 and R9 is independently selected from H and C1-3 alkyl; R4 is selected from: -OH; -SH; C1-6 alkoxy; and -NR10R11 wherein R10 and R11 are independently selected from H and C1-3 alkyl; and n is an integer from 0 to 2. Such compounds are particularly suitable for use in preventing, inhibiting or treating gastrointestinal disorders or conditions, cardiovascular diseases or disorders, and metabolic disorders, such as but not limited to primary sclerosing cholangitis (PSC), myocardial fibrosis, heart failure, type 2 diabetes and pre-diabetes. The invention further provides certain novel compounds, methods for their preparation and pharmaceutical compositions containing such compounds.

Disclosed is a method for treating a subject having primary sclerosing cholangitis, comprising administering to said subject an effective amount of a humanized antibody or antigen-binding fragment thereof having binding specificity for α4β7 integrin.

The present invention relates to the use of urine protein as a diagnostic marker for primary biliary cholangitis (PBC). The urine protein includes one or a combination of osteopontin (OPN), receptor activity-modifying protein 3 (RAMP3), and calcium-binding protein (S100A8). This application uses urine as a non-invasive test sample, making it more readily accepted by patients than blood. It is of great significance for the early, non-invasive diagnosis of PBC patients.